Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Piggyback” Lawsuits Spur NAD To Clarify Purpose Of Investigations

This article was originally published in The Tan Sheet

Executive Summary

Class-action lawsuits filed following National Advertising Division decisions raise concerns among firms participating in NAD’s self-regulatory process. The advertising industry’s voluntary self-regulation program clarifies that its findings do not indicate any laws have been violated.

You may also be interested in...



Class-Actions Increasing As Fallout From Regulatory Action

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.

Class-Actions Increasing As Fallout From Regulatory Action

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.

NAD Participation Poses Minimal Class-Action Risk – Attorney Analysis

An investigation led by attorney John Villafranco, a partner with Kelley Drye & Warren, suggests that the risk of incurring a consumer class-action lawsuit as a result of participating in NAD’s self-regulatory process is “much lower than many have assumed it to be.”

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel